Enhertu showed better outcomes in HR-positive, HER2-negative breast cancer, while Trodelvy was more effective in HR-negative, HER2-null tumors when used first. Real-world data from over 4,000 patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback